A Phase I, Placebo-Controlled, Double-Blind, 2-Period Crossover Study to Assess Cardiac and General Safety and Pharmacokinetics of a Single Subcutaneous Dose of 60 mg MGN1703 in Healthy Volunteers

Trial Profile

A Phase I, Placebo-Controlled, Double-Blind, 2-Period Crossover Study to Assess Cardiac and General Safety and Pharmacokinetics of a Single Subcutaneous Dose of 60 mg MGN1703 in Healthy Volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 02 Jun 2015

At a glance

  • Drugs Lefitolimod (Primary)
  • Indications Colorectal cancer; Non-small cell lung cancer; Solid tumours
  • Focus Adverse reactions
  • Sponsors Mologen
  • Most Recent Events

    • 02 Jun 2015 Results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
    • 30 Mar 2015 Findings from this study support the application scheme in the ongoing IMPULSE study in small cell lung cancer and IMPALA study in colorectal cancer, according to a Mologen media release.
    • 30 Mar 2015 Detailed pharmacokinetic and pharmacodynamic data from this trial were presented at the 2nd Immunotherapy of Cancer Conference (ITOC-2), according to a Mologen media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top